Thinle Chodon to Immunotherapy
This is a "connection" page, showing publications Thinle Chodon has written about Immunotherapy.
Connection Strength
0.759
-
Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):1025-1039.
Score: 0.455
-
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019 06 20; 7(1):156.
Score: 0.120
-
HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res. 2014 Sep 15; 74(18):5173-83.
Score: 0.085
-
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8.
Score: 0.066
-
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282.
Score: 0.033